Electra Therapeutics (NASDAQ:ETRA) Director Orbimed Advisors Llc Acquires 71,367 Shares of Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Orbimed Advisors Llc acquired 71,367 shares of the firm’s stock in a transaction on Wednesday, November 4th. The shares were acquired at an average price of $7.53 per share, with a total value of $537,393.51. Following the completion of the purchase, the director owned 5,189,871 shares in the company, valued at approximately $39,079,728.63. This trade represents a 1.39% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Orbimed Advisors Llc also recently made the following trade(s):

• On Thursday, November 5th, Orbimed Advisors Llc acquired 156,091 shares of Electra Therapeutics stock. The stock was acquired at an average cost of $7.31 per share, for a total transaction of $1,141,025.21.
• On Tuesday, November 3rd, Orbimed Advisors Llc acquired 245,113 shares of Electra Therapeutics stock. The stock was acquired at an average price of $7.86 per share, for a total transaction of $1,926,588.18.
• On Monday, September 21st, Orbimed Advisors Llc acquired 1,333,333 shares of Electra Therapeutics stock. The stock was acquired at an average price of $15.00 per share, for a total transaction of $19,999,995.00.

Electra Therapeutics Trading Down 7.8%

Shares of Electra Therapeutics stock opened at $7.35 on Friday. Electra Therapeutics, Inc. has a 1 year low of $6.86 and a 1 year high of $15.50.

Electra Therapeutics News Summary

Here are the key news stories impacting Electra Therapeutics this week:

• Positive Sentiment: Director Carl Gordon, associated with OrbiMed Advisors, reported purchases totaling 472,571 shares across November 3–5, worth approximately $3.6 million. The transactions increased his reported position, a sign of insider confidence. SEC filing
• Neutral Sentiment: Management plans to present at the Jefferies Global Healthcare Conference in London on November 18. The announcement provides an opportunity to discuss the company, but no new clinical or business developments were included. Conference announcement

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Zacks Research raised Electra Therapeutics to a “hold” rating in a research report on Wednesday, October 14th. Evercore assumed coverage on Electra Therapeutics in a report on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 price objective for the company. Jefferies Financial Group began coverage on Electra Therapeutics in a report on Tuesday, October 13th. They issued a “buy” rating and a $32.00 price objective for the company. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a research note on Saturday, September 26th. Finally, TD Cowen initiated coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Electra Therapeutics has a consensus rating of “Buy” and a consensus price target of $33.50.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.

Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.